Stock AnalizVericel Corp VCEL
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Vericel Corp (VCEL) is a healthcare company listed in the US with a market value of about $2.9B. In the twelve months to September 30, 2026 it had revenue of $324M and net income of $33M, a net margin of 10.3%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is future growth (5/5); the weakest is value (0/5).
Key numbers: a P/E of 89.0, a price to free cash flow of 50.2, 5-year revenue growth of 17% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 66% below the current price.
Score: 2.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $324M | $276M | $237M | $198M | $164M | $156M | $124M | $118M | $91M | $64M | $54M |
| Net income | $33M | $17M | $10M | -$3M | -$17M | -$7M | $3M | -$10M | -$8M | -$17M | -$20M |
| Free cash flow | $58M | $25M | -$6M | $15M | $10M | $21M | $15M | -$10M | -$3M | -$15M | -$21M |
| EPS (diluted) | $0.64 | $0.32 | $0.20 | $-0.07 | $-0.35 | $-0.16 | $0.06 | $-0.22 | $-0.20 | $-0.52 | $-1.18 |
| Net margin | 10.3% | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% | 2.3% | -8.2% | -9.0% | -27.0% | -36.0% |
| ROIC | — | 2.3% | 1.1% | -1.6% | -5.6% | -3.5% | 1.2% | -8.1% | -3.8% | -66.5% | -77.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $63.57, 12% above the current price; targets range from $55.00 to $75.00; the consensus rating is “Strong buy”; expected EPS is $0.73 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Vericel’s P/E ratio?
About 89.0, based on the last twelve months of diluted earnings per share (forward P/E about 54.7).
Is Vericel stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 66% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Vericel pay a dividend?
Not currently.
Is Vericel a good stock to buy?
We do not give buy or sell advice. Vericel scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.